New approaches to overriding stromal cell-associated chemoresistance, such as the use of agents that inhibit the CXCR4-SDF-1 axis, could potentially improve leukemia patient response and survival if developed as anticancer therapeutics. This evidence concerns the gene CXCL12 and leukemia.